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Abstract
Lupus or systemic lupus erythematosus is a chronic autoimmune disease with
systemic inflammation manifestations mainly in targeted organs. The appropriate
animal model for lupus is necessary. The induction method by using 2,6,10,14
tetramethylpentadecane (TMPD) reveals more complex manifestations than other
hydrocarbons. However, the autophagy of macrophages as an effect of TMPD
makes differences to make the decision in lupus biomarker as a targeted therapy
in lupus arthritis. Thus, this research focused on the role of CD68+IL-6 produced
by macrophages and total IL-6 in lupus in correlation to the arthritis severity. The
naïve and TMPD-treated groups (n=3) were induced by means of 0.5 ml TMPD i.p.
After 6 months, the mice were sacrificed then the fresh spleens were prepared
as isolated cells to be measured by using flow cytometry method. The knee joints
were prepared for histology observation. The statistical analysis was performed
by using T-test SPSS 22 version. The results showed the relative percentage of
CD68+IL-6+ in the TMPD-treated group increased significantly (P<0.05) with the
value of 62.38±9.97 %, compared to naïve group 49.70±2.34 %. Moreover, the total
IL-6 did not increase significantly (P>0.05). Meanwhile, the arthritis severity score of
the TMPD-treated group revealed severe erosion with the grade of 3.7±1.06, higher
significantly (P<0.05) than the naïve group (0.5±0.71). The joint spaces in both groups
were not significantly different. Finally, the observations gave the clear information
that despite the autophagy potency, the CD68+IL-6 and the arthritis severity score
were good markers in lupus preclinical study.
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1. Introduction
The animal model for lupus arthritis is rarely studied. Hydrocarbons like complete Fre-
und’s adjuvant (CFA) and 2,6,10,14 tetramethylpenta-decane (TMPD) reveal arthritis
manifestation although the similar baseline made by the hydrocarbons depends on
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the immunity of experimental animal used [1, 2]. TMPD reveals more complex mani-
festations which the joint disorder occurs as a result of systemic immune imbalance.
TMPD stimulates the production of IFN-α and IFN-𝛽 through immature monocytes
(Ly6Chi). The production of IFN-I and pro-inflammatory cytokines could be stimulated
by four main cell pathways by utilizing the differences between adaptor proteins or
signaling intermediate of TRIF (TLR 3 and 4), MyD88 (TLR 7, 8, and 9), IPS-1 (Rig-I-like
helicases, RLH)), and TBK1 or single-stranded RNA through TLR7 or TLR8 activates the
gene expression of IFN-α and 𝛽. The process involves the adaptor proteins MyD88,
some kinases and transcription factor interferon regulatory factor (IRF) 7 [3, 4]. All of
the pathways come to nuclear factor kappa B (NFκB). Moreover, the overproduction
of IFN-α and 𝛽 by means of TMPD highly depends on TLR7-MyD88-IRF7 pathways.
Finally, the organ disorders reveal the manifestation of glomerulonephritis, pulmonary
bleeding, and arthritis [4, 5] after the sufficient lupus-specific antibodies produced,
such as anti-Sm, anti-RNP, anti-ribosomal P, anti-Su, anti-dsDNA, and antichromatin
[6–8].
Besides, according to Foncesa [9] and Janicahsvilli [10], the pro-inflammatory
cytokines dominantly exist and then result in systemic inflammation. Cash [11] also
says that IL-6 is a targeted therapy which is potential for lupus. In contrary, the lupus
patients do not experience excessive inflammation except the local joint inflammation
when the flaring period happens. Deretic [12] and Zhu [13] explain the phenomenon
that TMPD could lead to autophagy of the macrophages in vitro and in vivo in the
spleen. There is no clear information about the impact of the autophagy on the
innate and adaptive immune system. Thus, in this research, we observed IL-6, a pro-
inflammatory cytokine produced by macrophages, in TMPD-treated lupus mice. IL-6
is suggested as a cytokine that has a direct role in the tissue damage [14]. The IL-6
which is produced by macrophages is CD68+IL-6. It was compared to the total IL-6 and
then be correlated to the arthritis severity score of the knee joint of the mice.
2. Materials and methods
2.1. Materials
Female Balb/c mice aged 4 weeks were received from LPPT UGM. These mice were
species pathogen free with the certificate number of 352/LP3HP/29/VII/2015. TMPD
(Pristane) was obtained from Sigma-Aldrich, Singapore. The anti-CD68 and anti-IL-6
were obtained fromBiogenesis, USA. The PBS and aqua bidestillata Ikapharmindowere
obtained from LDB Laboratory. The Verify reagent strips for urinalysis were obtained
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from CV. Rachmandjaya Surabaya. The ethyl acetate (pro analysis grade) was obtained
from Merck via PT Dianum Surabaya.
2.2. Methods
The experimental groups were a TMPD-treated group that was injected a volume of
0.5mL TMPD every 90 days (n=3) and a naïve group (n=3). The proteinuria measure-
ment was done every 7 days. At the end of the experiment, mice were sacrificed.
Then, the fresh spleen cells were immediately prepared to be 2measured by using
flow cytometry method. This CD68+IL-6+ measurement would be analyzed by means
of BD CellQuest program. Ethical clearance of this research was approved by ICUC of
VeterinaryMedicine Faculty Universitas Airlangga on January 12, 2016, with the number
of 526-KE.
3. Results and discussion
Inflammation markers in lupus arthritis are potential biomarkers of lupus arthritis for
drug development targets. Thus, it is a need to find markers that represent the disease
severity. In this case, the pro-inflammatory marker IL-6 has a direct correlation to
the tissue damage in spite of the macrophage autophagy in spleen which causes the
inflammation decrease. This experiment discusses the phenomenon by means of the
observation of the organoleptic data, the relative percentage of CD68+IL-6, the relative
percentage of total IL-6, and the arthritis severity score (ASS) based on the Pritzker [15]
scoring method.
In the organoleptic observation, the 6-month TMPD treated mice revealed a mild
walking abnormality about 2-3 days and then the behavior normal the next day. There
was no inflammation appeared in the joint, meanwhile the joint of the feet fingers
seemed more red than normal. After the induction time over, the mice were sacrificed,
and then the spleens were isolated. The spleen index was 227% than normal, reveals
the functional disorder of the spleen as a secondary lymphoid organ. Figure 1 shows
the organ appearance of TMPD-treated mice.
This white layer is predicted as a part of lipogranuloma as a result of TMPD induction
in the peritoneal cavity. The thicker layer forms lipid spots inside the peritoneal cavity,
but it does not interfere the liver and kidneys. This lipogranuloma is the trigger of the
inflammation and immune imbalance processes caused by TMPD. Fresh spleens were
collected in a closed tube which contained PBS, then the cells were prepared for flow
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Figure 1: The spleen of TMPD-treated mouse reveals the darker color, membrane-like lipid layer, and the
layer deposit in the middle of spleen surface.
T 1: The relative percentage of CD68+IL-6 + in the spleen cells of naïve and TMPD-treated groups.
Groups CD68+IL-6+ (%) ± SD
Naïve 49.70 ± 2.34
TMPD-treated 62.39 ± 9.97*
cytometry measurement. The processes were finished before 24 hours to keep the
living cells above 70%, with periodic observation every 2 hours. After the cell counting
finished, the data was analyzed by utilizing of BDCellQuest. The results are shown in
Figure 3, Table 1 and Table 2.
The gate (R1) was decided in order to make a border to be applied to all samples
in counting the IL-6 which is produced by macrophages. The chosen region was the
monocytes and granulocytes region, so the counting was more specific.
Figure 3 shows the increase of cell number and the increase of the number of
CD68+IL-6 in the up-right (UR) region of the sample. It was analyzed and then the
result is the significant increase (P<0.05) of the relative percentage of CD68+IL-6+.
Meanwhile, the total IL-6 is lower than the naïve mice. The decrease is not significant
(P>0.05).
Both results were not in line, so we observed the outcome of the pathology pro-
cesses to the joint of all mice. The results are shown in Figure 4 and Table 3. The
TMPD-treated mouse histology observation shows the erosion of hyaline layer in both
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Figure 2: The gating of the macrophages in the BD CellQuest program which was connected to the flow
cytometer.
Figure 3: The relative percentage profiles of CD68+IL-6+ as the results of flow cytometry analysis of the
fresh spleen cells of naïve group (a) and TMPD-treated group (b).
bones. The erosion seems to be involved in the compact bone destruction in a long
term.
The results lead to a prediction that dominant IL-6 in TMPD-treated lupus mice is IL-6
which is produced by macrophages (innate immune system). There are no differences
of total IL-6 in both groups. According to the high grade of the arthritis severity score
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T 2: The relative percentage of total IL-6 + in the spleen cells of naïve and TMPD-treated groups.
Groups CD68+IL-6+ (%) ± SD
Naïve 5.53 ± 0.22
TMPD-treated 5.30 ± 0.46
                                        
(a)
                                        
(b)
 
Figure 4: The histology observation of the joint of the naïve group (a) and TMPD-treated group (b) by
facilitating of inverted microscope Olympus CXK41 at the magnitude of 40x.
results in the TMPD-treated group, the IL-6 results seem not relevant. The score is
significantly higher (P<0.05) than the naïve one. Moreover, the joint space logically
shows the severity of inflammation in the joint. In this case, the mean of the joint
spaces of both groups are not significantly different (P>0.05). It is predicted that the
autophagymechanismwhich is stated by Zhu [13] occurs, so the joint disorder develops
without the equal increase of total IL-6. It might be a result of upregulation of TLR 3
on macrophages [16] causes the control of marker cells in rheumatoid diseases [17].
The immune complex deposit could perform erosion of the hyaline layer of the joint
[18, 19] and the imbalance of cytokines [20, 21].
4. Conclusion
In conclusion, CD68+IL6 and ASS are the appropriate markers to investigate new drugs
for lupus by using TMPD-treated mice.
T 3: The arthritis severity score (ASS) grade and the joint space of observed mice.
Groups ASS Grade Joint space (µm)
Naïve 0.5 ± 0.71 621.56 ± 334.52
TMPD-treated 3.7 ± 1.06* 672.34 ± 454.97
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